AZD7268 Safety and Tolerability Study

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Provision of signed, written, and dated Informed Consent prior to any study specific procedures

• Documented primary clinical diagnosis meeting criteria from the DSM-IV, Text Revision (APA 2000) for any of the following:

• 296.2x Major Depressive Disorder, Single Episode, or

• 296.3x Major Depressive Disorder, Recurrent

Exclusion Criteria:

• Patients with a secondary DSM-IV Axis I disorder other than GAD or social anxiety disorder (as assessed by MINI), provided the primary diagnosis is MDD. This diagnosis should have been made at least 6 months before enrollment

• Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status

• Patients whose current episode of depression started less than 4 weeks before enrollment